Hi, my name is Dr. Susan Baul. I'm an associate professor of medicine at the University of Alabama at Birmingham. And at this meeting, I was delighted to share some of the updated results from a phase one multicenter study of BMS 986393, which now has a name that's known as Arlocaptogen autosil or Arlocell. And we're updating the results from the phase one study here at this ash. So essentially, as we've discussed before, this is a phase one study in patients with relapsed and refractory multiple myeloma who've had at least three prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and a CD38 monoclonal antibody. In the study, prior BCMA-directed therapy was permitted. And essentially, we were looking at dose escalation between doses of 25 to 450 million, as well as trying to understand the safety and efficacy profile of this CAR T. So what we saw was on this study, we had a pretty heavily pretreated population, you know, meeting of five prior lines of therapy. Patients had high risk disease, 42%. And they also had extremity disease in about 46% of the cases. Almost half of the patients, 49%, were previously exposed to BCMA. So that was something unique. In addition, we had about 20% of those BCMA-exposed patients were actually refractory to their BCMA-directed therapy as well. So what we see is, you know, so the toxicity profile shows that there's lots of cytopenias, which is, you know, very similar to what's been seen with other products. This does resolve, you know, for the patients who had ongoing cytopenias beyond the first 30 days, the vast majority, 82%, did resolve. We see that the infection rate, particularly risk of high-grade infections, was low on the study. Overall, we saw less than 20% of the cases. And at the recommended phase to do is it was 12%. In the study, we had about 84 patients that did complete infusion of the Arlo cell. Within this population, 79 were available for efficacy. And among those, the overall response rate was 87% with a complete response or better rate of 53%. This is the first time we also saw initial results from the progression-free as well as overall survival. And in this efficacy-valuable population, that was 18.3 months median progression-free survival, which I think is very impressive in this particular patient population. What was also interesting was that the median PFS was about the same for patients who did and did not have prior BCMA-directed therapy. And what was really impressive to me was the overall survival. Median is obviously not reached at the time of most recent follow-up. The follow-up is about 16 months for these patients. And what we see is that the 12-month estimate of survival is 90%. So that's really exciting and encouraging. And hopefully, that will translate into improved outcomes for our patients. In terms of other toxicities, of course, it's a GPRC5T-directed therapy. So we do see skin, nail, and oral toxicities. But these are usually of much lower grade and much lower incidence than what is seen with T-cell-engager-type therapies that target GPRC5D. In almost 80% of the cases, additional intervention was not needed for these patients. We also saw cytokine release syndrome, which was in the order of 82%. High grade was only 4%. We see ICANNs, again, very similar to other studies, about 10% all grade and 2% high grade. We also saw some atypical sort of known ICANNs neurotoxicity that affected cost dizziness, ataxia, gait disturbances, et cetera, that were seen in about 12% of the cases. High grade in about 7%. These appear to be more dose-dependent. We're sort of working to understand why these occur and if there's a way to perhaps mitigate or diagnose these early. So that part of the study is really ongoing. As the phase two now accrues patients who hope to learn more about this toxicity.